Prolonged follow‐up after initial therapy with 2‐chlorodeoxyadenosine in patients with indolent non‐Hodgkin lymphoma

Abstract

A H2O/dimethyl sulfoxide(DMSO) mixture was used as the coagulation bath for the wet‐spun process of acrylonitrile/ammonium itaconate copolymers fibers. Diffusion coefficient of DMSO in the protofibers prepared by acrylonitrile/ammonium itaconate copolymers was determined. It has been found that diffusion coefficient of DMSO outflow of the protofibers prepared by acrylonitrile/ammonium itaconate copolymers synthesized by the solution polymerization is highest compared with those of acrylonitrile/ammonium itaconate copolymers synthesized by H2O/DMSO mixture suspension polymerization and the aqueous suspension polymerization. With an increase of copolymer concentration in the dope, diffusion coefficient of DMSO decreases continuously. Diffusion coefficient of DMSO increases along with the bath temperature, but the changes of diffusion coefficient values are less prominent as temperature goes beyond 60°C. When DMSO concentration in the coagulation bath was 55 wt %, the value of the diffusion coefficient of DMSO was minimal. Diffusion coefficient of H2O increases with the jet stretch minus ratio increasing. © 2006 Wiley Periodicals, Inc. J Appl Polym Sci 100: 4447–4451, 2006

Beyond hairy cell: the activity of cladribine in other hematologic malignancies

“…The median response duration was 1.3 years for partial responses and 3.1 years for CRs, with a median OS of 7 years. 46 Table 3 lists the other 6 reported cladribine studies in untreated indolent lymphoma patients, demonstrating its consistent activity across trials. Toxicity in the Cancer and Leukemia Group B study was considerable with 68% experiencing a grade 3 or 4 event, largely myelosuppression, and 8 patients had grade 3 infections.…”

“…The median duration of response varied widely from 7 to 23 months (Table 3). [46][47][48][49][50][51][52] The Cancer and Leukemia Group B conducted the most recent single-arm phase 2 trial, enrolling 44 treatment naive indolent lymphoma patients, the majority (73%) of whom had a follicular subtype. Patients received bolus cladribine at 0.14 mg/kg per day over 2 hours for 5 consecutive days every 28 days for up to 6 cycles, achieving an ORR of 98% (43 patients) and 32% CRs (14 patients).…”

“…46 Nonfollicular histologies appear equally sensitive to cladribine (Table 4). 45,[53][54][55][56][57][58][59][60] The largest single-arm phase 2 cladribine study in this setting enrolled 66 patients (80% untreated) with a variety of histologies, including follicular (40%), lymphoplasmacytic (30%), and MCL (20%).…”

Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low‐grade B‐cell non‐Hodgkin lymphoma patients

“…Importantly, our findings were similar to those of previously published phase 2 trials that evaluated initial treatment with cladribine alone in patients with LGNHL. 6,9 In the trial comparing fludarabine with CVP, no benefit regarding time to treatment failure was observed, even with significantly improved complete remission rates in the fludarabine arm. 4 Other phase 2 studies in untreated patients indicated fludarabine complete remission rates of 37% to 47% and overall response ratios up to 65%, which is consistent with our results in the cladribine alone arm.…”

“…However, toxicity, including myelosuppression and increased susceptibility to infections, was more pronounced than with standard chemotherapy. [4][5][6][7][8][9] Several studies that compared cyclophosphamide, vincristine, and prednisone combination to fludarabine-containing regimens were conducted in LGNHL, but cladribine use in first-line chemotherapy was not sufficiently documented in phase 3 studies. Thus, to establish the role of cladribine-containing regimens in this setting, including follicular lymphoma, lymphoplasmacytic lymphoma, marginalzone lymphoma, and small lymphocytic lymphoma, we designed this prospective, randomized, phase 3 study.…”